Growth Flags
show if company had growth for consecutive years
Target Price Range
Analyst price targets
Free account| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | 62 | 62 | 36 | 36 | 32 | 13 | 12 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 16 | 1 | 1 | 1 | — | — | 5 |
Revenue
|
|||
| — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | (38) | (66) | (60) | (57) | (113) | 98 | (30) |
EBT
|
|||
| — | — | — | (236.98%) | (7,315.30%) | (9,045.47%) | (3,902.97%) | 0.00% | 0.00% | (610.41%) |
EBT Margin
|
|||
| — | — | — | (38) | (66) | (60) | (57) | (113) | 98 | (23) |
Net Income
|
|||
| — | — | — | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | 17.27 | 0.78 | 0.42 | 0.86 | 0.00 | 0.00 | 1.49 |
Revenue/Sh
|
|||
| — | — | — | (40.82) | (57.14) | (38.26) | (50.34) | (56.63) | 33.50 | (7.18) |
Earnings/Sh
|
|||
| — | — | — | (30.07) | (47.76) | (33.19) | (26.51) | (16.98) | (8.50) | (7.52) |
Cash Flow/Sh
|
|||
| — | — | — | (0.43) | (0.18) | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | (30.51) | (47.94) | (33.05) | (26.51) | (16.99) | (8.50) | (7.52) |
Free CF/Sh
|
|||
| — | — | — | 110.19 | 93.09 | 40.91 | (6.65) | (45.84) | 10.18 | 11.96 |
Book Value/Sh
|
|||
| — | — | — | 1 | 1 | 2 | 2 | 2 | 3 | 3 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | 11.81 | 385.50 | 111.26 | 27.99 | — | — | 3.98 |
PS Ratio
|
|||
| — | — | — | 1.85 | 3.23 | 1.15 | 0.00 | — | — | 2.16 |
PB Ratio
|
|||
| — | — | — | 5.11 | 260.99 | 3.85 | 5.50 | — | — | 6.55 |
EV/Sales
|
|||
| — | — | — | (2.89) | (4.24) | (0.05) | (0.23) | — | — | (1.71) |
EV/FCF
|
|||
| — | — | — | (28) | (55) | (52) | (44) | (34) | (25) | (24) |
Op' Cash Flow
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | — | — |
Capex
|
|||
| — | — | — | (29) | (55) | (52) | (44) | (34) | (25) | (24) |
FCF
|
|||
| — | — | — | 102 | 107 | 64 | (8) | 34 | 29 | (4) |
Working Cap'
|
|||
| — | — | — | 0 | 0 | — | 1 | 1 | 1 | — |
Total Debt
|
|||
| — | — | — | (109) | (113) | (71) | (42) | (37) | (32) | (12) |
Net Debt
|
|||
| — | — | — | 103 | 108 | 64 | (11) | (91) | 29 | 39 |
Sh' Equity
|
|||
| — | — | — | (37.36%) | (56.97%) | (62.56%) | (140.33%) | (250.67%) | 250.94% | (34.36%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (64.66%) |
ROIC
|
|||
| — | — | — | (41.07%) | (62.53%) | (69.76%) | (320.14%) | 220.17% | (314.14%) | (113.18%) |
ROE
|
|||
predictions in italic, sparklines do not include predictions
Fiscal years to Dec 2022 · latest quarter Mar 2023
Aceragen, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| KTTA Pasithea Therapeutics Corp. | $17.2M | 0.0× | Compare |
| LPCN Lipocine Inc. | $17.2M | 0.0× | Compare |
| ALLR Allarity Therapeutics, Inc. | $17.3M | 0.0× | Compare |
| DYAI Dyadic International Inc. | $17.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PTN Palatin Technologies, Inc. | $17.5M | 2.4× | Compare |
| ANEB Anebulo Pharmaceuticals, Inc. | $17.6M | 0.0× | Compare |
| AKTX Akari Therapeutics PLC | $17.6M | 0.0× | Compare |
| BCDA BioCardia, Inc. | $16.2M | 0.0× | Compare |
Aceragen, Inc. (ACGN) key facts
- Aceragen, Inc. (ACGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million.
- Return on equity was −113.2% and debt-to-equity 0.00.
Aceragen, Inc. (ACGN) Latest News
No news matches these filters.